BXN Full Year 2026 Guidance

• Budgeting continued growth in Australian medical cannabis business
• Execution of new manufacturing and supply contracts with large Australian distributors and clinics
• Rapid expansion into international markets, including maiden $5.8m contract in Germany

Bioxyne Limited (ASX: BXN) has provided its full year FY2026 revenue guidance of $65,000,000 - $75,000,000, and EBITDA guidance of $11,500,000 - $13,500,000. The key highlights include: budgeting continued growth in BLS's Australian medical cannabis business with new contract wins and existing clients increasing forecast order volumes; execution of new manufacturing and supply contracts with large Australian distributors and clinics; and rapid expansion into international markets, including a maiden contract for $5.8 million into Germany, with purchase orders received. The first German delivery has been increased to 1,550kg (up from 580kg), with the initial shipment scheduled for September 2025 and a second shipment planned for November 2025. Bioxyne is positioned for significant growth in FY2026, attributable to further expansion of its business in Australia and entry into new high-growth opportunity markets including the UK, Germany and other EU countries. Contract manufacturing services provided the key driver of growth for the business in FY2025, with Pastilles, Flower packing, and Liquids (vape and oral mucosal oils) each representing roughly a third of revenues. Resale of flower API and GMP packed final product is expected to contribute substantially to growth in FY26.

FY2026 revenue guidance of $65,000,000 - $75,000,000, and EBITDA guidance of $11,500,000 - $13,500,000.

Bioxyne is positioned for significant growth in FY2026, attributable to further expansion of its business in Australia and entry into new high-growth opportunity markets including the UK, Germany and other EU countries.